

(19) AUSTRALIAN PATENT OFFICE

- (54) Title
Use of cholinesterase inhibitors for treating vascular depression
- (51)⁶ International Patent Classification(s)
A61K 31/27 (2006.01) 20060101ALI2005100
A61K 31/4453 ^{8BMEP} **A61K**
(2006.01) 31/55
A61K 31/55 (2006.01) 20060101ALI2005100
A61K 45/06 (2006.01) ^{8BMEP} **A61K**
A61K 31/27 45/06
20060101AFI2005100 20060101ALI2005100
^{8BMEP} **A61K** ^{8BMEP}
31/4453 PCT/EP2005/001715
- (21) Application No: 2005215134 (22) Application Date: 2005 .02 .18
- (87) WIPO No: W005/079784
- (30) Priority Data
- | | | |
|-------------|--------------|--------------|
| (31) Number | (32) Date | (33) Country |
| 60/545,871 | 2004 .02 .19 | US |
- (43) Publication Date : 2005 .09 .01
- (71) Applicant(s)
Novartis AG
- (72) Inventor(s)
Lane, Roger Michael
- (74) Agent/Attorney
Davies Collison Cave, 1 Nicholson Street, Melbourne, VIC, 3000
- (56) Related Art
Roman G C et al., Lancet Neurology, November 2002, Vol 1, No 1, pp426-436
Bentue-Ferrer et al., CNS Drugs, 2003, Vol 17, No 13, pp947-963
Roman G C, Current Opinion in Psychiatry, 2003, Vol 16, No 6 pp635-641
Sheline et al. Am J Med., 1997, Vol 1, No 102, pp54-59

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 September 2005 (01.09.2005)

PCT

(10) International Publication Number
WO 2005/079784 A1

- (51) International Patent Classification⁷: **A61K 31/27**,
31/4453, 31/55, 45/06, A61P 25/24
- (21) International Application Number:
PCT/EP2005/001715
- (22) International Filing Date: 18 February 2005 (18.02.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/545,871 19 February 2004 (19.02.2004) US
- (71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **LANE, Roger, Michael** [US/US]; 222 Riverside Drive #5D, New York, NY 10025-6809 (US).
- (74) Agent: **ROTH, Peter, R.**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AF, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CII, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PI, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 2005/079784 A1

(54) Title: USE OF CHOLINESTERASE INHIBITORS FOR TREATING VASCULAR DEPRESSION

(57) Abstract: The invention discloses the use of cholinesterase inhibitors in treating vascular depression.

USE OF CHOLINESTERASE INHIBITORS FOR TREATING VASCULAR DEPRESSION

The invention relates to the use of cholinesterase inhibitors in treating vascular depression.

FIELD OF THE INVENTION

The invention relates to the area of neurodegenerative diseases and, more particularly, to the treatment of vascular depression.

BACKGROUND OF THE INVENTION

There is a strong relationship between cerebrovascular disease, particularly subcortical white matter lesions and depression. See Lane et al., *German J Psych.*, Vol. 2, pp. 1-28 (1999). In addition, there is growing evidence for a sub-type of depression often – though not always – occurring in later life. Vascular damage to fronto-subcortical structures may be aetiological in late-life depression and it has also been termed "vascular depression". See Alexopoulos et al., *Am. J. Psychiatry*, Vol. 154, No. 4, pp. 562-565 (1997); and Krishnan et al., *Med. Hypotheses*, Vol. 44, pp. 77-145 (1995). It is known that diseases affecting the subcortex are associated with high rates of depression. Vascular depression may be diagnosed from a combination of depressive ideation, greater psychomotor disturbance, apathy, executive dysfunction on neuropsychological testing, neuroimaging abnormalities in the basal ganglia and white matter on MRI. Damage to end-arteries supplying subcortical-striato-palido-thalamo-cortical pathways may disrupt neurotransmitter circuitry involved in mood regulation, thus causing or inducing depression. Potentially, this may occur either via strategically placed infarcts, particularly affecting thalamocortical projections, or is the result of an overall threshold effect. In the absence of stroke, MRI studies of patients with late-onset depression have shown white matter hyperintensities in predominantly frontal lobes and basal ganglia, of possible vascular origin. See Greenwald et al., *Stroke*, Vol. 29, No. 3, pp. 613-617 (1998). There is extensive overlap between the aetiology and symptoms of vascular depression and subcortical vascular dementia – prominent psychomotor retardation, cognitive impairment, especially executive dysfunction and attention deficits and apathy are seen in both disorders, in addition to psychosis and affective disturbance. See Alexopoulos et al. (1997), *supra*; and Moretti et al., *Curr. Therapeutic Res.*, Vol. 63, pp. 443-458 (2002). Not surprisingly, patients with vascular

depression are at risk of developing subcortical vascular dementia. See Hickie et al., *Biol. Psychiatry*, Vol. 42, No. 5, pp. 367-374 (1997). Patients with vascular depression, defined by the presence of subcortical white matter hyperintensities on MRI, have a poorer response to anti-depressant treatment than patients with non-vascular depression. See Simpson et al., *Psychol. Med.*, Vol. 28, No. 5, pp. 1015-1026 (1998). In particular, cognitively impaired individuals with later life depression who respond to anti-depressant pharmacotherapy show cognitive improvements but some residual impairments, especially in memory and executive function. See Butters et al., *Research and Practices in Alzheimer's Disease*, Vol. 6, pp. 82-90 (2002); and Alexopoulos et al., *Am. J. Psychiatry*, Vol. 150, No. 11, pp. 1693-1699 (1993). The similarities between vascular depression and subcortical vascular dementia may mean that the response of depressive symptoms to rivastigmine in patients with subcortical vascular dementia [see Moretti et al. (2002), *supra*] suggests that rivastigmine, and possibly other cholinesterase inhibitors, may be useful as monotherapy or augmentation agents in vascular depression with evidence of subcortical vascular pathology.

Cholinesterase inhibitors including the aforementioned rivastigmine, are useful in treating a number of physiological disorders responsive to the activation of acetyl choline receptors, e.g., senile dementia, Alzheimer's Disease, Huntingdon's chorea, tardive dyskinesias, hyperkinesias, mania, acute confusion disorder, Down's syndrome, Friedrich's ataxia, multiple sclerosis and vascular dementia. However, there is nothing in the literature which teaches that cholinesterase inhibitors would be useful in treating late-onset vascular depression.

Conventional treatment of vascular depression involves the administration of anti-depressants which are utilized in treating non-vascular depression. However, although animal studies suggest that some anti-depressants promote neurological recovery after ischemic lesions, other anti-depressants inhibit recovery. Even when successful, anti-depressant therapy rarely alleviates the cognitive and executive function deficits associated with depression. More recently, drugs used in the prevention and treatment of cerebrovascular disease have been suggested to augment standard anti-depressant therapy in treating vascular depression, where early results have been mixed, at best. These include anti-cholesterinemic and anti-platelet agents, free radical scavengers, calcium channel blockers, glutamate *N*-methyl-*D*-aspartic acid receptor antagonists, gangliosides, amino-steroids and amphetamines. In view of the shortcomings of existing drugs, there is a need for a new method of treating vascular depression which alleviates the apathy, motor slowing,

2005215134 18 Sep 2008

- 3 -

cognitive impairment, attention deficits and executive function deficits associated with the condition, in addition to the symptoms of depression.

SUMMARY OF THE INVENTION

5

The present invention relates to the use of cholinesterase inhibitors for treating vascular depression.

In a first aspect, the present invention provides a method of treating vascular depression comprising administering to a subject in need of such treatment a
10 therapeutically effective amount of a cholinesterase inhibitor selected from the group consisting of donepezil, galanthamine and rivastigmine, in free form or in pharmaceutically acceptable salt form.

In a second aspect, the invention provides the use of a cholinesterase inhibitor, which cholinesterase inhibitor is selected from the group, consisting of donepezil,
15 galanthamine and rivastigmine, in free form or in pharmaceutically acceptable salt form, for the preparation of a medicament for the treatment of a disease in a subject in need thereof, characterized in that the said disease is vascular depression.

In one aspect, the invention relates to the use of a cholinesterase inhibitor in the monotherapy treatment of vascular depression, preferably in the monotherapy treatment
20 of late-onset vascular depression.

In another aspect, the invention relates to the use of a cholinesterase inhibitor in augmenting the anti-depressant therapy of vascular depression, preferably to augment the anti-depressant therapy of late-onset vascular depression.

2005215134 18 Sep 2008

- 3A -

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a method of treating vascular depression utilizing a cholinesterase inhibitor.

In one embodiment, the invention is directed to a method of treating vascular depression comprising administering to a subject in need of such treatment a therapeutically effective amount of a cholinesterase inhibitor. In a preferred embodiment, the invention is directed to a method of treating late-onset vascular depression.

In another embodiment, the invention relates to the use of cholinesterase inhibitors for the manufacture of medicaments for the treatment of vascular depression, preferably late-onset vascular depression.

In another embodiment, the invention relates to pharmaceutical compositions comprising, in combination, a cholinesterase inhibitor and an anti-depressant. More particularly, said embodiment relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of: 1) a cholinesterase inhibitor; and 2) an anti-depressant.

In a further embodiment, the invention is directed to a method of treating vascular depression comprising administering to a subject in need of such treatment a therapeutically

effective amount of a composition comprising, in combination, a cholinesterase inhibitor and at least one anti-depressant. In a preferred embodiment, the invention is directed to the use of said combination in treating late-onset vascular depression.

Although any cholinesterase inhibitor can be utilized in the practice of this invention, preferred cholinesterase inhibitors are those set forth in USP 4,948,807, more preferably rivastigmine hydrogentartrate; USP 4,895,841, more preferably donepezil hydrochloride; and USP 4,663,318, more preferably galanthamine hydrobromide.

For treating vascular depression, the appropriate dosage will of course vary depending upon, e.g., the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results are obtained when the cholinesterase inhibitor is administered in the form that it is marketed. More particularly, rivastigmine hydrogentartrate can be administered in tablet or capsule form or as a liquid oral concentrate under the tradename Exelon® in a total daily dosage of between 3 mg and 12 mg. Alternatively, rivastigmine can be administered transdermally in free base form, preferably via a transdermal patch of between 2 and 20 square centimeters (cm²). More preferably, rivastigmine can be administered at a dose of 9 mg in a patch of ~5 cm² or at a dose of 18 mg in a patch of ~10 cm², once every day. As regards to the other cholinesterase inhibitors, donepezil hydrochloride can be administered in tablet form under the tradename Aricept® in a total daily dosage of between 5 mg and 10 mg; and galanthamine bromide can be administered in tablet form under the tradename Reminyl® in a total daily dosage of between 12 mg and 24 mg, e.g., 12 mg twice a day.

As indicated above, the above-mentioned cholinesterase inhibitors can be utilized to augment the anti-depressant therapy in treating vascular depression. For example, they can be utilized to augment: 1) the SSRI anti-depressants, viz., Paxil®, Prozac®, Zoloft®, Celexa®, Lexapro®, etc.; 2) the SNRI anti-depressants, viz., Effexor®, etc.; 3) the MAO inhibitor anti-depressants, viz., Nardil®, Pamate®, etc.; 4) the tricyclic anti-depressants, viz., Elavil®, Norpramin®, etc.; and 5) other anti-depressants which work somewhat differently, viz., Wellbutrin® and Remeron®.

As with the cholinesterase inhibitors, the appropriate dosage of anti-depressants will, of course, vary depending upon, e.g., the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results are obtained when the anti-depressant is administered in the

form that is marketed. More particularly, Paxil® can be administered in tablet form in a total daily dosage of between 10 mg and 50 mg; Prozac® can be administered in tablet form in a total daily dosage of 20 mg; Zoloft® can be administered in tablet form in a total daily dosage of between 25 mg and 200 mg; Celexa® can be administered in tablet form in a total daily dosage of between 10 mg and 40 mg; Lexapro® can be administered in tablet form at a total daily dosage of between 10 mg and 20 mg; Effexor® can be administered in tablet form at a daily dosage of between 25 mg and 100 mg; Nardil® can be administered in tablet form at a total daily dosage of 15 mg; Parnate® can be administered in tablet form at a total daily dosage of 10 mg; Elavil®, which is now marketed as amitriptyline, can be administered in tablet form at a total daily dosage of between 10 mg and 150 mg; Norpramin® can be administered in tablet form at a total daily dosage of between 10 mg and 150 mg; Wellbutrin® can be administered in tablet form at a total daily dosage of between 75 mg and 100 mg; and Remeron® can be administered in tablet form at a total daily dosage of between 15 mg and 45 mg.

Moreover, the present invention also pertains to a pharmaceutical composition comprising, in combination, a cholinesterase inhibitor and an anti-depressant, preferably a pharmaceutical composition comprising, in combination, a cholinesterase inhibitor selected from Exelon®, Aricept® and Reminyl® and an anti-depressant selected from SSRI anti-depressants, SNRI anti-depressants, MAO inhibitor anti-depressants, tricyclic anti-depressants, Wellbutrin® and Remeron®, more preferably a pharmaceutical composition comprising, in combination, a cholinesterase inhibitor selected from Exelon®, Aricept® and Reminyl® and an anti-depressant selected from Paxil®, Prozac®, Zoloft®, Celexa®, Lexapro®, Effexor®, Nardil®, Parnate®, amitriptyline, Norpramin®, Wellbutrin® and Remeron®, most preferably a pharmaceutical composition comprising, in combination, Exelon® and an anti-depressant selected from Paxil®, Prozac®, Zoloft®, Celexa®, Lexapro®, Effexor®, Nardil®, Parnate®, amitriptyline, Norpramin®, Wellbutrin® and Remeron®.

In the above compositions, it should be understood that the cholinesterase inhibitor and the anti-depressant may be present in free form or in the form of a pharmaceutically acceptable salt together with a pharmaceutically acceptable carrier or diluent for simultaneous, separate or sequential use in treating vascular depression.

The active ingredients of the above compositions, i.e., the cholinesterase inhibitor and the anti-depressant, may also be part of a "kit" in the sense that the active ingredients can be dosed independently or by use of different fixed combinations with distinct amounts

of the active ingredients, i.e., simultaneously or at different times. The parts of the kit can then, e.g., be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for each component of the kit. Preferably, the time intervals are chosen such that the effect on the treated disease in the combined use of the parts is larger than the effect which would be obtained by use of only any one of the active ingredients.

Accordingly, the present invention also provides a commercial package comprising a combination as disclosed herein together with instructions for simultaneous or sequential use thereof in the treatment of vascular depression, preferably late-onset vascular depression. A preferred commercial package is one wherein one of the active ingredients is Exelon®.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

he reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

2005215134 17 Dec 2008

- 7 -

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method of treating vascular depression comprising administering to a subject in need of such treatment a therapeutically effective amount of a cholinesterase inhibitor selected from the group consisting of donepezil, galanthamine and rivastigmine, in free form or in pharmaceutically acceptable salt form.
2. A method according to Claim 1 for treating late-onset vascular depression.
3. A method according to Claim 1 or 2 wherein the cholinesterase inhibitor is selected from the group consisting of rivastigmine hydrogentartrate (Exelon[®]), donepezil hydrochloride (Aricept[®]) or galanthamine hydrobromide (Reminyl[®]).
4. A method according to Claim 3 wherein the cholinesterase inhibitor is rivastigmine hydrogentartrate (Exelon[®]).
5. A method according to Claim 4 wherein the rivastigmine hydrogentartrate (Exelon[®]) is administered at a daily dosage of between 3 mg and 12 mg.
6. A method according to Claim 1 wherein the cholinesterase inhibitor is rivastigmine which is administered transdermally in free base form.
7. A method according to Claim 6 comprising transdermal administration.
8. A method according to Claim 7 wherein the cholinesterase inhibitor is administered via a transdermal patch.
9. A method according to Claim 8 wherein rivastigmine is administered at a dose of 9 mg in a transdermal patch of ~5 cm², once every day.
10. A method according to Claim 8 wherein rivastigmine is administered at a dose of 18 mg in a transdermal patch of ~10 cm², once every day.
11. The use of a cholinesterase inhibitor, which cholinesterase inhibitor is selected from the group, consisting of donepezil, galanthamine and rivastigmine, in free form or in

- 8 -

pharmaceutically acceptable salt form, for the preparation of a medicament for the treatment of a disease in a subject in need thereof, characterized in that the said disease is vascular depression.

5 12. The use according to Claim 11, characterized in that the said disease is late-onset vascular depression.

13. The use according to Claim 11 or Claim 12, characterized in that the said cholinesterase inhibitor is selected from the group, consisting of donepezil hydrochloride
10 (Aricept®), galanthamine hydrobromide (Reminyl®) and rivastigmine hydrogentartrate (Exelon®).

14. The use according to any one of Claims 11 to 13, characterized in that the said cholinesterase inhibitor is rivastigmine hydrogentartrate (Exelon®).

15 15. The use according to Claim 14, characterized in that the said rivastigmine hydrogentartrate (Exelon®) is administered at a daily dosage of between 3 mg and 12 mg.

16. The use according to Claim 11 or Claim 12, characterized in that the said
20 cholinesterase inhibitor is rivastigmine in free form.

17. The use according to Claim 16, characterized in that the said medicament is a medicament for transdermal administration.

25 18. The use according to Claim 17, characterized in that the said medicament is a transdermal patch.

19. The use according to Claim 18, characterized in that the said transdermal patch has a size of ~5 cm² and is administered once a day at a dose of 9 mg.

30 20. The use according to Claim 18, characterized in that the said transdermal patch has a size of ~10 cm² and is administered once a day at a dose of 18 mg.

21. A method according to Claim 1 or a use according to Claim 11 substantially as
35 hereinbefore described and/or exemplified.

2005215134 18 Sep 2008